Beyond Bone Remodeling: Denosumab’s Multisystemic Benefits in Musculoskeletal Health, Metabolism, and Age-Related Diseases—A Narrative Review
<b>Background:</b> Denosumab, a receptor activator of nuclear factor kappa-Β ligand (RANKL) inhibitor, demonstrates therapeutic effects beyond traditional osteoporosis management through the RANK/RANKL/osteoprotegerin pathway. <b>Methods:</b> This narrative review analyzed 37...
Saved in:
| Main Authors: | Yi-Ting Hung, Wen-Tien Wu, Ru-Ping Lee, Ting-Kuo Yao, Kuang-Ting Yeh |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-03-01
|
| Series: | Biomedicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9059/13/3/732 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Advances in the Study of Denosumab Treatment for Osteoporosis and Sarcopenia in the Chinese Middle-Aged and Elderly Population
by: Li S, et al.
Published: (2024-12-01) -
Cellular and molecular mechanisms of osteoporosis: current concepts and future direction treatment
by: A. T. Dolzhenko, et al.
Published: (2016-06-01) -
THE ROLE OF CYTOKINE SYSTEM RANKL-RANK-OPG AND CATHEPSIN K IN THE PATHOGENESIS OF OSTEOPOROSIS: ACHIEVEMENTS AND PERSPECTIVES IN THE TREATMENT OF DISEASE
by: S. Sagalovsky, et al.
Published: (2015-10-01) -
Indicators of the osteoclastogenesis system in men with different clinical types of ankylosing spondylitis
by: T. A. Raskina, et al.
Published: (2015-06-01) -
Correlation of the differential expressions of RANK, RANKL, and OPG with obesity in the elderly population in Xinjiang
by: Liu Jinling, et al.
Published: (2025-08-01)